FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895554678> ?p ?o ?g. }

• W2895554678 endingPage "111" @default.
• W2895554678 startingPage "104" @default.
• W2895554678 abstract "Background Based on prospective vein bypass trials for lower leg ischemia, objective performance goals (OPG) were established by the Society for Vascular Surgery (SVS) and are used as a benchmark tool for open and endovascular treatments. This study aims to analyze OPG of all patients with critical limb ischemia (CLI) treated by open revascularization techniques at a tertiary care facility in routine practice. Methods From January 2005 to March 2013, 315 patients (mean age 72 years) with CLI were retrospectively included in this study. Inclusion criteria were patients with Fontaine stage III and IV, realized revascularization with open surgical procedures (bypass grafting or endarterectomy), or hybrid method (open + endovascular). Exclusion criteria were primary major amputations, patients with revascularization treatments of the index leg within the last 3 months, and missing aftercare. Primary end point was “amputation-free survival” (AFS), and secondary end point was “freedom from major adverse limb event + perioperative death (30 days)” (MALE + POD) according to the SVS. The technical end point was primary patency. Mean follow-up was 34 months. The following variables were studied: clinical stage (Fontaine), previous interventions, bypass material used, and site of the distal anastomosis. The statistical evaluation and preparation was carried out using the Kaplan–Meier estimator and the log-rank test. A multivariate analysis was performed using the Cox proportional hazards model. A P value ≤0.05 was considered to be statistically significant. Results A total of 128 patients (31%) fulfilling the adjusted SVS OPG criteria showed significantly better results for AFS, MALE + POD, and primary patency (P = 0.013, P = 0.015, P = 0.002, respectively). Regarding the AFS (1 year: 74%), multivariate analysis displayed significant worse results for patients with end-stage renal disease (hazard ratio [HR] 2.90, 95% confidence interval [CI] 1.83–4.60, P < 0.001) and Fontaine stage IV (HR 1.69, 95% CI 1.11–2.57, P = 0.015). Regarding MALE + POD (1 year: 64%), male patients (HR 0.64, 95% CI 0.46–0.90, P = 0.011) showed a significantly better outcome and patients without previous interventions of the index leg (HR 1.51, 95% CI 1.09–2.09, P = 0.013) showed a significantly worse outcome. Conclusions In this study, we were able to show that it is possible to reach the efficacy of OPGs set by SVS in a surgically treated all-comers cohort of CLI patients. Nevertheless, patients who did not fulfill the SVS OPG criteria showed significantly worse results for AFS and MALE + POD. Based on prospective vein bypass trials for lower leg ischemia, objective performance goals (OPG) were established by the Society for Vascular Surgery (SVS) and are used as a benchmark tool for open and endovascular treatments. This study aims to analyze OPG of all patients with critical limb ischemia (CLI) treated by open revascularization techniques at a tertiary care facility in routine practice. From January 2005 to March 2013, 315 patients (mean age 72 years) with CLI were retrospectively included in this study. Inclusion criteria were patients with Fontaine stage III and IV, realized revascularization with open surgical procedures (bypass grafting or endarterectomy), or hybrid method (open + endovascular). Exclusion criteria were primary major amputations, patients with revascularization treatments of the index leg within the last 3 months, and missing aftercare. Primary end point was “amputation-free survival” (AFS), and secondary end point was “freedom from major adverse limb event + perioperative death (30 days)” (MALE + POD) according to the SVS. The technical end point was primary patency. Mean follow-up was 34 months. The following variables were studied: clinical stage (Fontaine), previous interventions, bypass material used, and site of the distal anastomosis. The statistical evaluation and preparation was carried out using the Kaplan–Meier estimator and the log-rank test. A multivariate analysis was performed using the Cox proportional hazards model. A P value ≤0.05 was considered to be statistically significant. A total of 128 patients (31%) fulfilling the adjusted SVS OPG criteria showed significantly better results for AFS, MALE + POD, and primary patency (P = 0.013, P = 0.015, P = 0.002, respectively). Regarding the AFS (1 year: 74%), multivariate analysis displayed significant worse results for patients with end-stage renal disease (hazard ratio [HR] 2.90, 95% confidence interval [CI] 1.83–4.60, P < 0.001) and Fontaine stage IV (HR 1.69, 95% CI 1.11–2.57, P = 0.015). Regarding MALE + POD (1 year: 64%), male patients (HR 0.64, 95% CI 0.46–0.90, P = 0.011) showed a significantly better outcome and patients without previous interventions of the index leg (HR 1.51, 95% CI 1.09–2.09, P = 0.013) showed a significantly worse outcome. In this study, we were able to show that it is possible to reach the efficacy of OPGs set by SVS in a surgically treated all-comers cohort of CLI patients. Nevertheless, patients who did not fulfill the SVS OPG criteria showed significantly worse results for AFS and MALE + POD." @default.
• W2895554678 created "2018-10-12" @default.
• W2895554678 creator A5024664147 @default.
• W2895554678 creator A5029702853 @default.
• W2895554678 creator A5036904296 @default.
• W2895554678 creator A5078922954 @default.
• W2895554678 date "2019-02-01" @default.
• W2895554678 modified "2023-09-27" @default.
• W2895554678 title "Objective Performance Goals for Surgical Treatment of Critical Limb Ischemia" @default.
• W2895554678 cites W1821110075 @default.
• W2895554678 cites W1984684769 @default.
• W2895554678 cites W1986400872 @default.
• W2895554678 cites W2024960685 @default.
• W2895554678 cites W2067229002 @default.
• W2895554678 cites W2092082358 @default.
• W2895554678 cites W2107726960 @default.
• W2895554678 cites W2111512532 @default.
• W2895554678 cites W2111984022 @default.
• W2895554678 cites W2118743200 @default.
• W2895554678 cites W2140136269 @default.
• W2895554678 cites W2142237138 @default.
• W2895554678 cites W2144985796 @default.
• W2895554678 cites W2148325862 @default.
• W2895554678 cites W2152088217 @default.
• W2895554678 cites W2155942116 @default.
• W2895554678 cites W2159618206 @default.
• W2895554678 cites W2162412409 @default.
• W2895554678 cites W2168393911 @default.
• W2895554678 cites W2185467918 @default.
• W2895554678 cites W2226336146 @default.
• W2895554678 cites W2262457591 @default.
• W2895554678 cites W2465379097 @default.
• W2895554678 cites W2587316139 @default.
• W2895554678 doi "https://doi.org/10.1016/j.avsg.2018.07.050" @default.
• W2895554678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30287288" @default.
• W2895554678 hasPublicationYear "2019" @default.
• W2895554678 type Work @default.
• W2895554678 sameAs 2895554678 @default.
• W2895554678 citedByCount "2" @default.
• W2895554678 countsByYear W28955546782023 @default.
• W2895554678 crossrefType "journal-article" @default.
• W2895554678 hasAuthorship W2895554678A5024664147 @default.
• W2895554678 hasAuthorship W2895554678A5029702853 @default.
• W2895554678 hasAuthorship W2895554678A5036904296 @default.
• W2895554678 hasAuthorship W2895554678A5078922954 @default.
• W2895554678 hasConcept C126322002 @default.
• W2895554678 hasConcept C141071460 @default.
• W2895554678 hasConcept C168563851 @default.
• W2895554678 hasConcept C203092338 @default.
• W2895554678 hasConcept C2776204877 @default.
• W2895554678 hasConcept C2777010666 @default.
• W2895554678 hasConcept C2778789114 @default.
• W2895554678 hasConcept C2779464278 @default.
• W2895554678 hasConcept C2781099653 @default.
• W2895554678 hasConcept C31174226 @default.
• W2895554678 hasConcept C500558357 @default.
• W2895554678 hasConcept C50382708 @default.
• W2895554678 hasConcept C71924100 @default.
• W2895554678 hasConceptScore W2895554678C126322002 @default.
• W2895554678 hasConceptScore W2895554678C141071460 @default.
• W2895554678 hasConceptScore W2895554678C168563851 @default.
• W2895554678 hasConceptScore W2895554678C203092338 @default.
• W2895554678 hasConceptScore W2895554678C2776204877 @default.
• W2895554678 hasConceptScore W2895554678C2777010666 @default.
• W2895554678 hasConceptScore W2895554678C2778789114 @default.
• W2895554678 hasConceptScore W2895554678C2779464278 @default.
• W2895554678 hasConceptScore W2895554678C2781099653 @default.
• W2895554678 hasConceptScore W2895554678C31174226 @default.
• W2895554678 hasConceptScore W2895554678C500558357 @default.
• W2895554678 hasConceptScore W2895554678C50382708 @default.
• W2895554678 hasConceptScore W2895554678C71924100 @default.
• W2895554678 hasLocation W28955546781 @default.
• W2895554678 hasLocation W28955546782 @default.
• W2895554678 hasOpenAccess W2895554678 @default.
• W2895554678 hasPrimaryLocation W28955546781 @default.
• W2895554678 hasRelatedWork W1970090329 @default.
• W2895554678 hasRelatedWork W2000276814 @default.
• W2895554678 hasRelatedWork W2057398300 @default.
• W2895554678 hasRelatedWork W2063036634 @default.
• W2895554678 hasRelatedWork W2098520058 @default.
• W2895554678 hasRelatedWork W2277967466 @default.
• W2895554678 hasRelatedWork W2605470762 @default.
• W2895554678 hasRelatedWork W2844153221 @default.
• W2895554678 hasRelatedWork W3194895825 @default.
• W2895554678 hasRelatedWork W4282929913 @default.
• W2895554678 hasVolume "55" @default.
• W2895554678 isParatext "false" @default.
• W2895554678 isRetracted "false" @default.
• W2895554678 magId "2895554678" @default.
• W2895554678 workType "article" @default.